Research institution
Hebei Medical University Fourth Hospital Clinical Trials
Studies where Hebei Medical University Fourth Hospital is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 49Breast Cancer
Trastuzumab/Pertuzumab With Fulvestrant and Culmerciclib in HR+/HER2+ Early Breast Cancer
This phase II single-arm study is designed to evaluate the neoadjuvant efficacy of a chemotherapy-free regimen consisting of trastuzumab, pertuzumab, Culmerciclib, and fulvestrant in patients with treatment-naïve stage II-III…
- Trial name
- NCT07857226
- Testing
- Trastuzumab (or biosimilar), Pertuzumab, Culmerciclib
- Volunteers
- 31 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma
Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell Carcinoma
This study aims to evaluate the efficacy and safety of neoadjuvant sacituzumab tirumotecan (SKB264/MK-2870) combined with toripalimab in patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC).
- Trial name
- NCT07823270
- Testing
- Sacituzumab tirumotecan, Toripalimab
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma
Paclitaxel Polymeric Micelles and Cisplatin Plus Sintilimab as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Locally advanced Esophageal Squamous Cell Carcinoma (ESCC) has poor prognosis with standard therapies. Neoadjuvant immunochemotherapy improves pathological response rates, but optimal regimens remain undefined.
- Trial name
- NCT07799077
- Testing
- Paclitaxel polymer micelles for injection and cisplatin combined with sintilimab
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Hebei Medical University Fourth Hospital
Breast Cancer
QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy
This study will evaluate whether adding QL1706 (iparomlimab and tuvonralimab) to neoadjuvant endocrine therapy improves tumor response in patients with hormone receptor-positive (HR-positive), human epidermal growth factor…
- Trial name
- NCT07782840
- Testing
- Iparomlimab and Tuvonralimab (QL1706), Aromatase Inhibitor (AI), CDK4/6 inhibitor
- Volunteers
- 40 people
- Sponsor
- Hebei Medical University Fourth Hospital
Oligometastatic Clear Cell Renal Cell Carcinoma
SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma
This is a phase II clinical trial testing whether a combination of stereotactic ablative radiotherapy (SABR), axitinib, and toripalimab is effective and safe for treating oligometastatic clear cell renal cell carcinoma (a type of…
- Trial name
- NCT07744932
- Testing
- axitinib plus toripalimab, SABR
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Hebei Medical University Fourth Hospital
Rectal Cancer Stage I
Tumor Local Excision +Postoperative Adjuvant Chemoradiotherapy for T1-2N0M0 Low/Ultra-Low Rectal Cancer
This study is a single-center, single-arm, prospective clinical trial designed to evaluate the efficacy of local excision followed by postoperative chemoradiotherapy in patients with early-stage low/ultra-low rectal cancer.
- Trial name
- NCT06949098
- Testing
- Local Tumor Resection, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hebei Medical University Fourth Hospital
Hepatocellular Carcinoma
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
This project is a prospective, open-label, randomized controlled clinical study. It plans to enroll 60 patients with unresectable HCC and no distant metastasis, randomly assigned to the experimental group and the control group…
- Trial name
- NCT07179900
- Testing
- QL1706, Radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hebei Medical University Fourth Hospital
Colon Cancer
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR/MSS T4M0 stage…
- Trial name
- NCT06949111
- Testing
- radiotherapy, CAPOX, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Efficacy and Safety of Short-course Radiotherapy in Total Neoadjuvant Therapy Combined With Enlonstobart for pMMR Locally Advanced Rectal Cancer
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Efficacy and safety of short-course radiotherapy in total neoadjuvant therapy combined with enlonstobart for pMMR locally advanced rectal cancer
- Trial name
- NCT07448077
- Testing
- Experimental: short-course radiotherapy and immunotherapy, Chemoradiotherapy
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin Plus Cisplatin and Radiotherapy in LA-ESCC
This study is a prospective, single-arm, single-center Phase Ib clinical trial of Becotatug Vedotin in combination with cisplatin and concurrent radiotherapy for locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT07697040
- Testing
- Becotatug Vedotin Combined with Cisplatin and Concurrent Radiotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Hebei Medical University Fourth Hospital